mesothelioma Author Manuscript NIH Public Access Inhibitor ...
Vorinostat also failed to demonstrate single agent activity in 14 patients with advanced stage non-small cell lung cancer that had progressed following mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006; 7:257–61. [PubMed: 16512979] 9. ... Access Doc
MesothelioMa Update Aggressive Management Under Debate
MesothelioMa Update Aggressive management under debate Christopher W. Lee, MD, FRCPC The incidence of mesothelioma in Canada has been steadily increasing since the 1970s. inhibitor, vorinostat, in the second-line setting has also reported negative results.14 ... Read Content
Posters, 8th Annual BTOG Conference, 2010
2 Evaluation of c-FLIP as a target for vorinostat in mesothelioma J. Hurwitz, K. Redmond, K. McLaughlin, D Belfast, N Ireland, United Kingdom Background: Mesothelioma typically presents at a late stage and therefore carries a poor prognosis in the majority of cases. Chemotherapy is the ... Retrieve Full Source
Immune Effectors Required For The Therapeutic Activity Of ...
E27157-2 OncoImmunology Volume 2 Issue 11 DNAM1).22 Conversely, Fiegler and col-laborators showed that vorinostat lim-its the recognition of malignant cells by ... Retrieve Here
No comments:
Post a Comment